Comparison Between Iliopsoas Block (IPB) and Pericapsular Nerve Group (PENG) Block on Postoperative Analgesia and Functional Recovery After Total Hip Arthroplasty Surgery: a Double-blinded Randomized Clinical Trial

Background:
In recent years, regional anesthesia has become more popular because it can reduce pain and the need for strong pain medications like morphine. For hip surgery, the PENG block is already known to be effective. A newer method, called the iliopsoas plane block (IPB), is very similar and has also shown good results in hip arthroscopy. However, these two techniques have never been directly compared in patients undergoing hip replacement surgery using the posterior approach.
Goal:
This study aims to see if the IPB is just as effective as the PENG block for controlling pain and helping patients recover well after hip replacement surgery.
Method:
118 adult patients scheduled for hip replacement under spinal anesthesia will be randomly assigned to receive either: IPB: 7 ml of Ropivacaine 7.5 mg/ml PENG: 14 ml of Ropivacaine 3.75 mg/ml Both injections are given under ultrasound guidance 30 minutes before spinal anesthesia. Neither the patient, the surgeon, nor the data collector will know which technique was used.
Post-Surgery Care:
All patients will receive standard pain relief, including:
Paracetamol every 6 hours Etoricoxib once a day Morphine via a patient-controlled pump for 48 hours
Main Outcome Measured:
The primary goal is to compare pain during movement 6 hours after surgery, using a pain scale from 0 (no pain) to 10 (worst pain). The study will consider the two blocks equivalent if the difference in average pain scores is less than 1 point.
Other Outcomes:
Total morphine used in 48 hours Pain scores at rest and during movement at various time points Walking ability (2- and 6-minute walk tests, and timed-up-and-go test) Quality of recovery (using the QoR-15 questionnaire) Side effects of morphine Patient satisfaction Length of hospital stay
Safety:
Both techniques are safe and already used in clinical practice. Ultrasound guidance minimizes risks like nerve injury, bleeding, or infection.
Conclusion:
If the IPB is shown to be as effective as the PENG block, both can be considered reliable options for pain control and early recovery after hip replacement surgery.

Start Date01 Oct 2025

Sponsor / Collaborator

University of Liege

[+1]

NCT07031518

/ RecruitingNot ApplicableIIT

Pilot Study to Identify and Validate Digital Biomarkers in Osteoarthritis of the Knee

To date, treatment options for knee osteoarthritis remain limited, and their clinical evaluation is complex due to the day-to-day fluctuations in symptoms.
Hospital tests provide a point-in-time measurement that is influenced by various factors (fatigue, recent activity, weather, etc.), making reliable assessment difficult. The aim of the study is to assess the feasibility and acceptability of monitoring actual activity using the Syde® portable device in up to 30 subjects. Numerical variables derived from data collected by Syde® will be compared with conventional on-site clinical assessment criteria and with data from healthy participants, in order to identify a reliable and robust metric, thereby improving treatment evaluation and personalised patient management.
MAIN OBJECTIVES
* Evaluate the use of the device
* Identify numerical variables and determine the optimal time window for evaluation
Patients will have two visits: one at inclusion and a second two months later. They will wear Syde® magneto-inertial sensors, one on each ankle, for the month following the initial visit, then a Syde® sensor on the ankle and another on the wrist on the side of the non-dominant hand for the following month. The total duration of the recording period is two months.

Start Date14 May 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire de Liege

[+2]

NCT06916871

/ Not yet recruitingNot ApplicableIIT

Optimizing Care for Diabetic Patients in Hospitalized Rehabilitation Through Structured Education.

A large number of patients at the Neurological and Functional Rehabilitation Centre of the University Hospital of Liège have associated pathologies, including diabetes. These patients may have diabetes-related complications that require recurrent hospitalizations in an acute structure or in rehabilitation. One of the ways to limit complications is to set up patient education.
1. Objectives
* To compare the impact of management through formal education with that of awareness.
* To evaluate the impact on knowledge of structured education.
* To evaluate the impact of structured education on the quality of life experienced by diabetic patients.
* Identify the patient's level of satisfaction with the education sessions.
* To evaluate the impact of structured education on the biological improvement of glycated hemoglobin.
* To evaluate the impact of structured education on diabetes-related complications.
2. Working Hypothesis The implementation of structured diabetes education allows "patients to acquire, or maintain, the skills they need to manage their lives as well as possible despite the constraints of chronic disease... ".
3. Study population All diabetic patients hospitalized in all care units.
4. Collection tools and techniques Collection tools
1. "Diabetes Knowledge Questionnaire". 2. SF-36 Health Questionnaire. 3. Satisfaction questionnaire for structured sessions on diabetes. 4. Questionnaire to identify complications and/or re-hospitalizations after your stay in rehabilitation.
Collection technology At admission (D+1)
* Validation of inclusion and exclusion criteria.
* Submission and distribution of the information and consent form.
* Obtaining informed consent from the patient.
* Distribution of collection tools 1 and 2 (collection on D+2).
* Control of glycated hemoglobin. At the end of hospitalization (D-2)
* Distribution of collection tools 1, 2 and 3 on D-2 before the release (collection on D-1).
* Control of glycated hemoglobin. 3 months after the end of hospitalization
* Sending collection tools 1, 2 and 4 by post. The patient will be invited to complete them and return them by post.
* The patient will be invited to take a blood test for glycated hemoglobin.

Start Date07 Apr 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire de Liege

100 Clinical Results associated with Centre Hospitalier Universitaire de Liege

0 Patents (Medical) associated with Centre Hospitalier Universitaire de Liege

826

Literatures (Medical) associated with Centre Hospitalier Universitaire de Liege

01 Aug 2025·CLINICAL GENETICS

Genotype–Phenotype Correlations, Treatment, and Prognosis of Children With Early‐Onset (Neonatal) Marfan Syndrome

Article

Author: Houben, Michiel ; Lai, Lillian ; Pals, Gerard ; Menke, Leonie A ; van der Leest, Eva C ; Warnink-Kavelaars, Jessica ; Mills, Lindsay ; Zhytnik, Lidiia ; Jira, Petr ; van der Hulst, Annelies E ; Jacquemart, Caroline ; de Waard, Vivian ; Lunshof, Bert L

ABSTRACT:

Early‐onset Marfan syndrome (eoMFS) is a severe and rare form of Marfan syndrome characterized by severe atrioventricular valve insufficiency developing before or shortly after birth. It is unclear which factors (interventions and/or genotype) influence survival. Forty‐one individuals with eoMFS with a fibrillin‐1 gene (FBN1) variant in exon 24–32 (CRCh37) were included. At the last follow‐up, 14/41 (34%) were alive (8 months‐18 years) and 27/41 (66%) were deceased. Median age of death was 1 month and 88% of the deaths occurred before 5 months of age. More individuals alive past the age of 16 months versus those who were deceased before that age had undergone cardiovascular surgery at an older age (13 months, range 3–72, vs. 2 months, range 2–2, p = 0.03). Survival was better in those with single amino acid substitutions/small in‐frame deletions than in those with large in‐frame deletions (p = 0.007), but variants involving a cysteine substitution in an EGF‐like domain versus those involving other amino acids did not significantly influence survival. EoMFS ranges from a (pre‐)neonatal life‐threatening disorder to a disorder with enhanced survival, creating a window for cardiovascular surgery. Individuals with single amino acid substitutions/small in‐frame deletions had better survival compared to those with variants significantly impacting exon 24–32 length.

01 Jul 2025·MOLECULAR THERAPY

A precision medicine approach to primary immunodeficiency disease: Ataluren strikes nonsense mutations once again

Article

Author: Colige, Alain ; Moutschen, Michel ; Carollo, Pietro S ; Lentini, Laura ; Melfi, Raffaella ; Pace, Andrea ; Ricci, Davide ; Delvenne, Philippe ; Grimbacher, Bodo ; Corrao, Federica ; Fiduccia, Ignazio ; Tutone, Marco ; Pibiri, Ivana ; Genovese, Francesco ; Perriera, Riccardo

Primary immunodeficiency diseases (PIDs) are associated with multiple genetic alterations including mutations of the lipopolysaccharide responsive Beige anchor (LRBA) gene. Nonsense mutations in the LRBA gene resulting in premature termination codons cause the loss of LRBA protein expression in PID. We evaluated the impact of a translational readthrough-inducing drug (TRID) ataluren as a nonsense suppression therapy in a PID patient with a homozygous stop codon mutation in exon 30 of LRBA. A precision medicine approach allowed us to pass from "in silico" to "in vitro" to the "bedside": following the in vitro treatment of patient-derived primary fibroblasts with ataluren, we observed a restoration of the LRBA protein expression and localization. In silico predictions suggested LRBA retained function after readthrough. Based on the successful experimental and computational results we treated the patient with ataluren resulting in an improvement of his clinical symptoms and quality of life. Importantly, the clinical symptoms were associated with a recovery of LRBA expression in liver biopsies post-treatment compared with pre-treatment. Our results provide a proof of concept demonstrating that ataluren, can rescue LRBA expression in PID. This work highlights the potential for personalized precision medicine approaches to be exploited for different genetic diseases due to premature termination codons.

24 Jun 2025·ACTA CARDIOLOGICA

Commentary on 'Effect of dapagliflozin on the no-reflow phenomenon in patients with acute myocardial infarction and type iI diabetes mellitus'.

Article

Author: Davidsen, Cedric

News (Medical) associated with Centre Hospitalier Universitaire de Liege

10 Mar 2025

·firstwordpharma.com

J&J's oral IL-23 peptide icotrokinra delivers in UC after psoriasis triumph

Johnson & Johnson's icotrokinra (JNJ-2113) met the primary endpoint of a Phase IIb ulcerative colitis (UC) study, building on its recent success in psoriasis. The IL-23-blocking oral peptide could also boost the company's efforts to stay ahead in immunology as Stelara (ustekinumab) stares down biosimilar competition.In the ANTHEM-UC study, J&J tested three once-daily doses of icotrokinra and found that the highest one led to a clinical response in 63.5% of patients after 12 weeks, compared to just 27% for placebo. The drug also showed "meaningful differences" on secondary measures like clinical remission, with 30.2% of patients on the highest dose achieving remission versus 11.1% for placebo. J&J said the benefits kept improving through week 28, with a favourable safety profile.The trial enrolled 252 patients with moderately to severely active UC who'd had an inadequate response or intolerance to conventional therapy. More ANTHEM-UC results will be shared at upcoming medical congresses."These impressive findings show the potential of icotrokinra to transform the treatment paradigm… by offering a distinctive combination of therapeutic benefit, tolerability, and convenience with a once-daily oral treatment," said Esi Lamousé-Smith, gastroenterology disease area lead at J&J, in a release Monday.The icotrokinra results complement J&J's recent efforts to strengthen its IL-23 lineup, including September's FDA approval of Tremfya (guselkumab) for UC with intravenous induction and subcutaneous maintenance, and a pending application for a fully subcutaneous regimen. According to data presented last month, Tremfya's SC induction demonstrated significantly higher rates of clinical remission (27.6% vs 6.5%) and response (65.6% vs 34.5%) versus placebo at week 12 in the Phase III ASTRO trial.Both icotrokinra and Tremfya are being positioned to help offset expected revenue declines from Stelara, which saw a 4.6% global sales drop in 2024 as biosimilars enter the market.The UC data for icotrokinra follows its strong showing in psoriasis at the American Academy of Dermatology (AAD) meeting over the weekend. The ICONIC-ADVANCE 1 and 2 trials not only met their primary endpoints of achieving clear or nearly clear skin, but also demonstrated superiority to Bristol Myers Squibb's oral TYK2 inhibitor Sotyktu (deucravacitinib). See – ViewPoints: AAD25 – J&J leadership tells how icotrokinra is upping the ante across the board in psoriasis.

Clinical ResultPhase 3Drug ApprovalPhase 2

100 Deals associated with Centre Hospitalier Universitaire de Liege

100 Translational Medicine associated with Centre Hospitalier Universitaire de Liege

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 31 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 2

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Mesenchymal Stem Cell(University of Liege)	Crohn Disease More	Phase 2
CMV-Ig	Cytomegalovirus Infections More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis